AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 11 - (NewsRx.com & NewsRx.net) -- An interleukin 12-engineered allogeneic cell vaccine prevents HER-2/neu transgenic breast cancer.
According to recent research published in the journal Cancer Research, "This study evaluated the ability of cytokine-engineered allogeneic (H-2degrees) HER-2/neu-positive cells to prevent tumor development in mammary cancer-prone virgin female BALB/c (H-2[superscript]d) mice transgenic for the transforming rat HER-2/neu oncogene (BALB-neuT mice). Repeated vaccinations with cells engineered to release interleukin (IL)-2, IL-12, IL-15, or IFN-gamma showed that IL-12-engineered cell vaccines had the most powerful immunopreventive activity, with >80% of 1-year-old BALB-neuT mice free of tumors, respectively."
"On the contrary, all of the untreated mice and all of the mice vaccinated with IL-12-engineered cells lacking either HER-2/neu or allogeneic antigens developed mammary carcinomas within 22 or 33 weeks," said Carla de Giovanni at the University of Bologna and collaborators throughout Italy. "Whole mount, histology, immunohistochemistry, and gene expression profile analysis showed that vaccination with IL-12-engineered cells maintained 26-week mammary glands free of neoplastic growth, with a gene expression profile that clustered with that of untreated preneoplastic glands."
"The IL-12-engineered cell vaccine elicited a high production of IFN-gamma and IL-4 and a strong anti-HER-2/neu antibody response," ...
Source: HighBeam Research, IL-12-engineered allogeneic cell vaccine prevents breast cancer.